FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery

Synopsis

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery An earlier study at Memorial Sloan Kettering Cancer Center (NCT04165772) evaluated Jemperli alone in 50 patients with previously untreated dMMR or MSI-H locally advanced rectal cancer.

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.